Conditions

Sodium-glucose cotransporter 2 (SGLT2) inhibitors were created to treat diabetes, but noted to ameliorate cardiovascular events. 

Health plans with high deductibles require thousands of dollars out-of-pocket and have a known association with delays in treatment; a repeated cross-sectional study found they are also associated with medication non-adherence.

The case for why an SGLT2 inhibitor or GLP-1 receptor agonist should be initiated early in diabetes treatment, regardless of whether the patient is on insulin therapy.

Artificial intelligence fingerprints gut flora, linking clusters of microbial species with type 1 diabetes development.

Researchers showed that elevated blood pressure is a modifiable risk factor for new-onset type 2 diabetes.

The mean age at diagnosis of diabetes for non-Hispanic Black and Hispanic adults was 4-7 years earlier than for non-Hispanic white adults.

Many foods are marked with the whole-grain stamp of approval, but are these products equivalent in terms of glycemic control?

A program testing type 1 diabetes patients’ C-peptide levels found that approximately half of the group had a different form of diabetes.

A prospective study found an increased risk for fractures and falls among older women with type 2 diabetes.

Efpeglenatide has proven to significantly reduce several risk factors for cardiovascular and kidney disease.